HYDERABAD: Indian Immunological Limited intends to begin production of this drug material of indigenously produced Covid-19 vaccine Covaxin from June 15 and ship the initial batch to Bharat Biotech from July.
IIL will begin with 2-3 million doses daily and will be ramping up this around 6-7 million doses a month from the close of the year also scale this up to 10-15 million gallons each month, IIL managing director Dr Anand Kumar stated on Friday.
Bharat Biotech has tied up by IIL, and it is a centre setup National Dairy Development Board (NDDB), for producing the drug material of Covaxin as part of attempts to quickly accelerate production of this desi vaccine.
Dr Kumar also stated they’re turning their Karakapatla production unit at Genome Valley, situated near the Bharat Biotech centre, to some Bio Safety Level-3 (BSL3) centre for fabricating the Covaxin drug material, even as they’re taking up building of some other block.
The Karakapatla centre was also a BSL 2+ centre at which IIL was creating rabies vaccines, that has been altered to other centers of the business.
IIL was declared a grant of Rs 60 crore below the Mission COVID Suraksha which was launched from the department of biotechnology (DBT) for improving Covid-19 vaccine manufacturing capacities in the nation.
Aside from producing the drug material for Covaxin, IIL is currently focusing on its very own live attenuated Covid-19 vaccine in collaboration with Griffith University of Australia.
The vaccine is now undergoing creature trials and is anticipated to be prepared to be used in 2022.
IIL is currently working on a different Covid-19 vaccine along with the animal trials have been underway now and is expected to emerge another year for individual vaccination.